Advertisement
Advertisement
TVTX
Travere Therapeutics, Inc. Common Stock
27.56
USDSponsored
+0.78
+2.89%
Mar 25, 16:00 UTC -4
Closed
Pre-Market
27.35
-0.21
-0.76%
TVTX Earnings Reports
Positive Surprise Ratio
TVTX beat 17 of 41 last estimates.
41%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$139.52M
/-$0.20
Implied change from Q4 25 (Revenue/ EPS)
+7.58%
/-766.67%
Implied change from Q1 25 (Revenue/ EPS)
+70.71%
/-57.45%
Travere Therapeutics, Inc. Common Stock earnings per share and revenue
On Feb 19, 2026, TVTX reported earnings of 0.03 USD per share (EPS) for Q4 25, beating the estimate of -0.12 USD, resulting in a 124.92% surprise. Revenue reached 129.69 million, compared to an expected 145.08 million, with a -10.61% difference. The market reacted with a -14.63% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 139.52 million USD, implying an decrease of -766.67% EPS, and increase of 7.58% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were Travere Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Travere Therapeutics, Inc. Common Stock reported EPS of $0.03, beating estimates by 124.92%, and revenue of $129.69M, -10.61% below expectations.
How did the market react to Travere Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -14.63%, changed from $34.10 before the earnings release to $29.11 the day after.
When is Travere Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Travere Therapeutics, Inc. Common Stock's next earnings report?
Based on 11
analysts, Travere Therapeutics, Inc. Common Stock is expected to report EPS of -$0.20 and revenue of $139.52M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement